[1]
|
Boehncke, W.H., Boehncke, S., Tobin, A.M. and Kirby, B. (2011) The “Psoriatic March”: A Concept of How Severe Psoriasis May Drive Cardiovascular Comorbidity. Experimental Dermatology, 20, 303-307.
https://doi.org/10.1111/j.1600-0625.2011.01261.x
|
[2]
|
Gelfand, J.M., Dommasch, E.D., Shin, D.B., Azfar, R.S., Kurd, S.K., Wang, X. and Troxel, A.B. (2009) The Risk of Stroke in Patients with Psoriasis. Journal of Investigative Dermatology, 129, 2411-2418. https://doi.org/10.1038/jid.2009.112
|
[3]
|
Mansouri, B., Kivelevitch, D., Natarajan, B., Joshi, A.A., Ryan, C., Benjegerdes, K., Schussler, J.M., Rader, D.J., Reilly, M.P., Menter, A. and Mehta, N.N. (2016) Comparison of Coronary Artery Calcium Scores between Patients with Psoriasis and Type 2 Diabetes. JAMA Dermatology, 152, 1244-1253.
https://doi.org/10.1001/jamadermatol.2016.2907
|
[4]
|
Augustin, M. and Radtke, M.A. (2014) Quality of Life in Psoriasis Patients. Expert Review of Pharmacoeconomics and Outcomes Research, 14, 559-568.
https://doi.org/10.1586/14737167.2014.914437
|
[5]
|
Quintard, B., Constant, A., Bouyssou-Gauthier, M.L., Paul, C., Truchetet, F., Thomas, P., Guiguen, Y. and Taieb, A. (2011) Validation of a Specific Health-Related Quality of Life Instrument in a Large Cohort of Patients with Psoriasis: The QualiPso Questionnaire. Acta Dermato-Venereologica, 91, 660-665.
https://doi.org/10.2340/00015555-1137
|
[6]
|
Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J. and Troxel, A.B. (2006) Risk of Myocardial Infarction in Patients with Psoriasis. JAMA, 296, 1735-1741. https://doi.org/10.1001/jama.296.14.1735
|
[7]
|
Furue, M., Tsuji, G., Chiba, T. and Kadono, T. (2017) Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Internal Medicine, 56, 1613-1619.
|
[8]
|
Shahwan, K.T. and Kimball, A.B. (2015) Psoriasis and Cardiovascular Disease. Medical Clinics of North America, 99, 1227-1242.
https://doi.org/10.1016/j.mcna.2015.08.001
|
[9]
|
Takeshita, J., Grewal, S., Langan, S.M., Mehta, N.N., Ogdie, A., Van Voorhees, A.S. and Gelfand, J.M. (2017) Psoriasis and Comorbid Diseases: Epidemiology. Journal of the American Academy of Dermatology, 76, 377-390.
https://doi.org/10.1016/j.jaad.2016.07.064
|
[10]
|
Ryan, C. and Kirby, B. (2015) Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities. Dermatologic Clinics, 33, 41-55.
https://doi.org/10.1016/j.det.2014.09.004
|
[11]
|
Kaye, J.A., Li, L. and Jick, S.S. (2008) Incidence of Risk Factors for Myocardial Infarction and Other Vascular Diseases in Patients with Psoriasis. British Journal of Dermatology, 159, 895-902. https://doi.org/10.1111/j.1365-2133.2008.08707.x
|
[12]
|
Shah, K., Mellars, L., Changolkar, A. and Feldman, S.R. (2017) Real-World Burden of Comorbidities in US Patients with Psoriasis. Journal of the American Academy of Dermatology, 77, 287-292. https://doi.org/10.1016/j.jaad.2017.03.037
|
[13]
|
Ma, L., Li, M., Wang, H., Li, Y. and Bai, B. (2014) High Prevalence of Cardiovascular Risk Factors in Patients with Moderate or Severe Psoriasis in Northern China. Archives of Dermatological Research, 306, 247-251.
https://doi.org/10.1007/s00403-013-1437-3
|
[14]
|
Masson, W., Rossi, E., Galimberti, M.L., Krauss, J., Estrada, J.N., Galimberti, R. and Cagide, A. (2017) Mortality in Patients with Psoriasis. A Retrospective Cohort Study. Medicina Clínica, 148, 483-488. https://doi.org/10.1016/j.medcli.2016.12.011
|
[15]
|
Gelfand, J.M., Troxel, A.B., Lewis, J.D., Kurd, S.K., Shin, D.B., Wang, X., Margolis, D.J. and Strom, B.L. (2007) The Risk of Mortality in Patients with Psoriasis: Results from a Population-Based Study. Archives of Dermatology, 143, 1493-1499.
https://doi.org/10.1001/archderm.143.12.1493
|
[16]
|
Mehta, N.N., Azfar, R.S., Shin, D.B., Neimann, A.L., Troxel, A.B. and Gelfand, J.M. (2010) Patients with Severe Psoriasis Are at Increased Risk of Cardiovascular Mortality: Cohort Study Using the General Practice Research Database. European Heart Journal, 31, 1000-1006. https://doi.org/10.1093/eurheartj/ehp567
|
[17]
|
Siegel, D., Devaraj, S., Mitra, A., Raychaudhuri, S.P., Raychaudhuri, S.K. and Jialal, I. (2013) Inflammation, Atherosclerosis, and Psoriasis. Clinical Reviews in Allergy and Immunology, 44, 194-204. https://doi.org/10.1007/s12016-012-8308-0
|
[18]
|
Augustin, M., Vietri, J., Tian, H. and Gilloteau, I. (2017) Incremental Burden of Cardiovascular Comorbidity and Psoriatic Arthritis among Adults with Moderate-to-Severe Psoriasis in Five European Countries. Journal of the European Academy of Dermatology and Venereology, 31, 1316-1323.
https://doi.org/10.1111/jdv.14286
|
[19]
|
Feldman, S.R., Tian, H., Gilloteau, I., Mollon, P. and Shu, M. (2017) Economic Burden of Comorbidities in Psoriasis Patients in the United States: Results from a Retrospective U.S. Database. BMC Health Services Research, 17, 337.
https://doi.org/10.1186/s12913-017-2278-0
|
[20]
|
Benson, M.M. and Frishman, W.H. (2015) The Heartbreak of Psoriasis: A Review of Cardiovascular Risk in Patients with Psoriasis. Cardiology in Review, 23, 312-316.
|
[21]
|
Coumbe, A.G., Pritzker, M.R. and Duprez, D.A. (2014) Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors. The American Journal of Medicine, 127, 12-18. https://doi.org/10.1016/j.amjmed.2013.08.013
|
[22]
|
Armstrong, E.J., Harskamp, C.T. and Armstrong, A.W. (2013) Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies. Journal of the American Heart Association, 2, e000062.
https://doi.org/10.1161/JAHA.113.000062
|
[23]
|
Ogdie, A., Yu, Y., Haynes, K., Love, T.J., Maliha, S., Jiang, Y., Troxel, A.B., Hennessy, S., Kimmel, S.E., Margolis, D.J., et al. (2015) Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A Population-Based Cohort Study. Annals of the Rheumatic Diseases, 74, 326-332.
https://doi.org/10.1136/annrheumdis-2014-205675
|
[24]
|
Wu, J.J., Choi, Y.M. and Bebchuk, J.D. (2015) Risk of Myocardial Infarction in Psoriasis Patients: A Retrospective Cohort Study. Journal of Dermatological Treatment, 26, 230-234. https://doi.org/10.3109/09546634.2014.952609
|
[25]
|
Lai, Y.C. and Yew, Y.W. (2016) Psoriasis as an Independent Risk Factor for Cardiovascular Disease: An Epidemiologic Analysis Using a National Database. Journal of Cutaneous Medicine and Surgery, 20, 327-333.
|
[26]
|
Li, W.Q., Han, J.L., Manson, J.E., Rimm, E.B., Rexrode, K.M., Curhan, G.C. and Qureshi, A.A. (2012) Psoriasis and Risk of Nonfatal Cardiovascular Disease in U.S. Women: A Cohort Study. British Journal of Dermatology, 166, 811-818.
https://doi.org/10.1111/j.1365-2133.2011.10774.x
|
[27]
|
Levesque, A., Lachaine, J. and Bissonnette, R. (2013) Risk of Myocardial Infarction in Canadian Patients with Psoriasis: A Retrospective Cohort Study. Journal of Cutaneous Medicine and Surgery, 17, 398-403.
https://doi.org/10.2310/7750.2013.13052
|
[28]
|
Lin, H.W., Wang, K.H., Lin, H.C. and Lin, H.C. (2011) Increased Risk of Acute Myocardial Infarction in Patients with Psoriasis: A 5-Year Population-Based Study in Taiwan. Journal of the American Academy of Dermatology, 64, 495-501.
https://doi.org/10.1016/j.jaad.2010.01.050
|
[29]
|
Shiba, M., Kato, T., Funasako, M., Nakane, E., Miyamoto, S., Izumi, T., Haruna, T. and Inoko, M. (2016) Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan. PLoS ONE, 11, e0149316.
https://doi.org/10.1371/journal.pone.0149316
|
[30]
|
Abuabara, K., Azfar, R.S., Shin, D.B., Neimann, A.L., Troxel, A.B. and Gelfand, J.M. (2010) Cause-Specific Mortality in Patients with Severe Psoriasis: A Population-Based Cohort Study in the U.K. British Journal of Dermatology, 163, 586-592.
https://doi.org/10.1111/j.1365-2133.2010.09941.x
|
[31]
|
Stern, R.S. and Huibregtse, A. (2011) Very Severe Psoriasis Is Associated with Increased Noncardiovascular Mortality but Not with Increased Cardiovascular Risk. Journal of Investigative Dermatology, 131, 1159-1166.
https://doi.org/10.1038/jid.2010.399
|
[32]
|
Wakkee, M., Herings, R.M. and Nijsten, T. (2010) Psoriasis May Not Be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort. Journal of Investigative Dermatology, 130, 962-967. https://doi.org/10.1038/jid.2009.321
|
[33]
|
Dowlatshahi, E.A., Kavousi, M., Nijsten, T., Ikram, M.A., Hofman, A., Franco, O.H. and Wakkee, M. (2013) Psoriasis Is Not Associated with Atherosclerosis and Incident Cardiovascular Events: The Rotterdam Study. Journal of Investigative Dermatology, 133, 2347-2354. https://doi.org/10.1038/jid.2013.131
|
[34]
|
Ahlehoff, O., Gislason, G., Lamberts, M., Folke, F., Lindhardsen, J., Larsen, C.T., Torp-Pedersen, C. and Hansen, P.R. (2015) Risk of Thromboembolism and Fatal Stroke in Patients with Psoriasis and Nonvalvular Atrial Fibrillation: A Danish Nationwide Cohort Study. Journal of Internal Medicine, 277, 447-455.
https://doi.org/10.1111/joim.12272
|
[35]
|
Samarasekera, E.J., Neilson, J.M., Warren, R.B., Parnham, J. and Smith, C.H. (2013) Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 133, 2340-2346.
https://doi.org/10.1038/jid.2013.149
|
[36]
|
Xu, T. and Zhang, Y.H. (2012) Association of Psoriasis with Stroke and Myocardial Infarction: Meta-Analysis of Cohort Studies. British Journal of Dermatology, 167, 1345-1350. https://doi.org/10.1111/bjd.12002
|
[37]
|
Chiang, C.H., Huang, C.C., Chan,W.L., Huang, P.H., Chen, Y.C., Chen, T.J., Chung, C.M., Lin, S.J., Chen, J.W. and Leu, H.B. (2012) Psoriasis and Increased Risk of Ischemic Stroke in Taiwan: A Nationwide Study. The Journal of Dermatology, 39, 279-281. https://doi.org/10.1111/j.1346-8138.2011.01401.x
|
[38]
|
Ahlehoff, O., Gislason, G.H., Jorgensen, C.H., Lindhardsen, J., Charlot, M., Olesen, J.B., Abildstrom, S.Z., Skov, L., Torp-Pedersen, C. and Hansen, P.R. (2012) Psoriasis and Risk of Atrial Fibrillation and Ischaemic Stroke: A Danish Nationwide Cohort Study. European Heart Journal, 33, 2054-2064.
https://doi.org/10.1093/eurheartj/ehr285
|
[39]
|
Ahlehoff, O., Gislason, G.H., Charlot, M., Jorgensen, C.H., Lindhardsen, J., Olesen, J.B., Abildstrom, S.Z., Skov, L., Torp-Pedersen, C. and Hansen, P.R. (2011) Psoriasis Is Associated with Clinically Significant Cardiovascular Risk: A Danish Nationwide Cohort Study. Journal of Internal Medicine, 270, 147-157.
https://doi.org/10.1111/j.1365-2796.2010.02310.x
|
[40]
|
Prodanovich, S., Kirsner, R.S., Kravetz, J.D., Ma, F., Martinez, L. and Federman, D.G. (2009) Association of Psoriasis with Coronary Artery, Cerebrovascular, and Peripheral Vascular Diseases and Mortality. Archives of Dermatology, 145, 700-703.
https://doi.org/10.1001/archdermatol.2009.94
|
[41]
|
Raaby, L., Ahlehoff, O. and De Thurah, A. (2017) Psoriasis and Cardiovascular Events: Updating the Evidence. Archives of Dermatological Research, 309, 225-228.
https://doi.org/10.1007/s00403-016-1712-1
|
[42]
|
Ahlehoff, O., Gislason, G.H., Lindhardsen, J., Olesen, J.B., Charlot, M., Skov, L., Torp-Pedersen, C. and Hansen, P.R. (2011) Prognosis Following First-Time Myocardial Infarction in Patients with Psoriasis: A Danish Nationwide Cohort Study. Journal of Internal Medicine, 270, 237-244.
https://doi.org/10.1111/j.1365-2796.2011.02368.x
|
[43]
|
Mallbris, L., Akre, O., Granath, F., Yin, L., Lindelof, B., Ekbom, A. and Stahle-Backdahl, M. (2004) Increased Risk for Cardiovascular Mortality in Psoriasis Inpatients but Not in Outpatients. European Journal of Epidemiology, 19, 225-230.
https://doi.org/10.1023/B:EJEP.0000020447.59150.f9
|
[44]
|
Parsi, K.K., Brezinski, E.A., Lin, T.C., et al. (2012) Are Patients with Psoriasis Being Screened for Cardiovascular Risk Factors? A Study of Screening Practices and Awareness among Primary Care Physicians and Cardiologists. Journal of the American Academy of Dermatology, 67, 357-362.
https://doi.org/10.1016/j.jaad.2011.09.006
|
[45]
|
Kimball, A.B., Szapary, P., Mrowietz, U., et al. (2012) Underdiagnosis and Undertreatment of Cardiovascular Risk Factors in Patients with Moderate to Severe Psoriasis. Journal of the American Academy of Dermatology, 67, 76-85.
https://doi.org/10.1016/j.jaad.2011.06.035
|
[46]
|
Takeshita, J., Wang, S., Shin, D.B., et al. (2015) Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom. JAMA Dermatology, 151, 161-169. https://doi.org/10.1001/jamadermatol.2014.2094
|
[47]
|
Alamdari, H.S., Gustafson, C.J., Davis, S.A., et al. (2013) Psoriasis and Cardiovascular Screening Rates in the United States. Journal of Drugs in Dermatology, 12, e14-e19.
|
[48]
|
Manalo, I.F., Gilbert, K.E. and Wu, J.J. (2015) Survey of Trends and Gaps in Dermatologists’ Cardiovascular Screening Practices in Psoriasis Patients: Areas Still in Need of Improvement. Journal of the American Academy of Dermatology, 73, 872-874.
|
[49]
|
Friedewald, V.E., Cather, J.C., Gelfand, J.M., et al. (2008) AJC Editor’s Consensus: Psoriasis and Coronary Artery Disease. American Journal of Cardiology, 102, 1631-1643. https://doi.org/10.1016/j.amjcard.2008.10.004
|
[50]
|
Eckel, R.H., Jakicic, J.M., Ard, J.D., et al. (2014) 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129, S76-S99. https://doi.org/10.1161/01.cir.0000437740.48606.d1
|
[51]
|
Mehta, N.N., Krishnamoorthy, P., Yu, Y.D., Khan, O., Raper, A., Van Voorhees, A., Troxel, A.B. and Gelfand, J.M. (2012) The Impact of Psoriasis on Ten-Year Framingham Risk. Journal of the American Academy of Dermatology, 67, 796-798.
https://doi.org/10.1016/j.jaad.2012.05.016
|
[52]
|
Mehta, N.N., Yu, Y., Pinnelas, R., Krishnamoorthy, P., Shin, D.B., Troxel, A.B., et al. (2011) Attributable Risk Estimates of Severe Psoriasis on Major Adverse Cardiac events. The American Journal of Medicine, 124, e771-e776.
|
[53]
|
Peters, M.J., Symmons, D.P., McCarey, D., Dijkmans, B.A., Nicola, P., Kvien, T.K., et al. (2010) EULAR Evidence-Based Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Forms of Inflammatory Arthritis. Annals of the Rheumatic Diseases, 69, 325-331.
https://doi.org/10.1136/ard.2009.113696
|
[54]
|
Hennekens, C.H., Dyken, M.L. and Fuster, V. (1997) Aspirin as a Therapeutic Agent in Cardiovascular Disease: A Statement for Healthcare Professionals from the American Heart Association. Circulation, 96, 2751-2753.
https://doi.org/10.1161/01.CIR.96.8.2751
|
[55]
|
IMS Health (2014) IMS Health. 1 October 2013 to 30 September 2014.
|
[56]
|
IMS Health (2013) Top Global Products 2013.
|
[57]
|
Chan K.L., Dumesnil, J.G. and Tam, J. (2011) Effect of Rosuvastatin on C-Reactive Protein and Progression of Aortic Stenosis. American Heart Journal, 161, 1133-1139.
|
[58]
|
Koh, K.K., Quon, M.J., Sakuma, I., et al. (2013) Differential Metabolic Effects of Rosuvastatin and Pravastatin in Hypercholesterolemic Patients. International Journal of Cardiology, 166, 509-515. https://doi.org/10.1016/j.ijcard.2011.11.028
|
[59]
|
Brault, M., Ray, J., Gomez, Y., Mantzoros, C.S. and Daskalopoulou, S.S. (2014) Statin Treatment and New-Onset Diabetes: A Review of Proposed Mechanisms. Metabolism, 63, 735-745. https://doi.org/10.1016/j.metabol.2014.02.014
|
[60]
|
Pijak, M.R., Huzicka, I. and Gazdik, F. (2005) Coxibs and Cardiovascular Risk. Canadian Medical Association Journal, 173, 852. https://doi.org/10.1503/cmaj.1050128
|
[61]
|
Kearney, P.M., Baigent, C., Godwin, J., Halls, H., Emberson, J.R. and Patrono, C. (2006) Do Selective Cyclo-Oxygenase-2 Inhibitors and Traditional Non-Steroidal Anti-Inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-Analysis of Randomized Trials. British Medical Journal, 332, 1302-1308.
https://doi.org/10.1136/bmj.332.7553.1302
|
[62]
|
Nashel, D.J. (1986) Is Atherosclerosis a Complication of Long-Term Corticosteroid Treatment? The American Journal of Medicine, 80, 925-929.
https://doi.org/10.1016/0002-9343(86)90639-X
|
[63]
|
Lan, C.C., Ko, Y.C., Yu, H.S., Wu, C.S., Li, W.C., Lu, Y.W., Chen, Y.C., Chin, Y.Y., Yang, Y.H. and Chen, G.S. (2012) Methotrexate Reduces the Occurrence of Cerebrovascular Events among Taiwanese Psoriatic Patients: A Nationwide Population-Based Study. Acta Dermato-Venereologica, 92, 349-352.
https://doi.org/10.2340/00015555-1283
|
[64]
|
De Vecchis, R., Baldi, C. and Palmisani, L. (2016) Protective Effects of Methotrexate against Ischemic Cardiovascular Disorders in Patients Treated for Rheumatoid Arthritis or Psoriasis: Novel Therapeutic Insights Coming from a Meta-Analysis of the Literature Data. Anatolian Journal of Cardiology, 16, 2-9.
|
[65]
|
Haverkate, F., Thompson, S.G., Pyke, S.D., Gallimore, J.R. and Pepys, M.B. (1997) Production of C-Reactive Protein and Risk of Coronary Events in Stable and Unstable Angina. The Lancet, 349, 462-466.
https://doi.org/10.1016/S0140-6736(96)07591-5
|
[66]
|
Everett, B. et al. (2013) Rationale and Design of the Cardiovascular Inflammation Reduction Trial: A Test of the Inflammatory Hypothesis of Atherothrombosis. American Heart Journal, 166, 199-207. https://doi.org/10.1016/j.ahj.2013.03.018
|
[67]
|
Ridker, P.M., et al. (2018) Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. The New England Journal of Medicine, 380, 752-762.
|
[68]
|
Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al. (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. The New England Journal of Medicine, 359, 2195-2207.
https://doi.org/10.1056/NEJMoa0807646
|
[69]
|
Ridker, P.M., Everett, B.M., Thuren, T., et al. (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 377, 1119-1131. https://doi.org/10.1056/NEJMoa1707914
|
[70]
|
Ridker, P.M., MacFadyen, J.G., Thuren, T., Everett, B.M., Libby, P., Glynn, R.J. and CANTOS Trial Group (2017) Effect of Interleukin-1β Inhibition with Canakinumab on Incident Lung Cancer in Patients with Atherosclerosis: Exploratory Results from a Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 390, 1833-1842.
|
[71]
|
Sehested, T.S.G., Bjerre, J., Ku, S., et al. (2019) Cost-Effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology, 4, 218-135.
https://doi.org/10.1001/jamacardio.2018.4566
|
[72]
|
Gelfand, G.M. et al. (2018) 393 A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and Placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial. Journal of Investigative Dermatology, 138, S67. https://doi.org/10.1016/j.jid.2018.03.400
|
[73]
|
https://www.medpagetoday.com/rheumatology/arthritis/78224
|
[74]
|
Abuabara, K., Lee, H. and Kimball, A.B. (2011) The Effect of Systemic Psoriasis Therapies on the Incidence of Myocardial Infarction: A Cohort Study. British Journal of Dermatology, 165, 1066-1073.
https://doi.org/10.1111/j.1365-2133.2011.10525.x
|
[75]
|
Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S.L., Iversen, L., Lasthein, S., Gniadecki, R., Dam, T.N., Torp-Pedersen, C., et al. (2013) Cardiovascular Disease Event Rates in Patients with Severe Psoriasis Treated with Systemic Anti-Inflammatory Drugs: A Danish Real-World Cohort Study. Journal of Internal Medicine, 273, 197-204. https://doi.org/10.1111/j.1365-2796.2012.02593.x
|
[76]
|
Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L.E., Lasthein, S., Lindhardsen, J., Kristensen, S.L., Torp-Pedersen, C., et al. (2015) Cardiovascular Outcomes and Systemic Anti-Inflammatory Drugs in Patients with Severe Psoriasis: 5-Year Follow-Up of a Danish Nationwide Cohort. Journal of the European Academy of Dermatology and Venereology, 29, 1128-1134.
https://doi.org/10.1111/jdv.12768
|
[77]
|
Chin, Y.Y., Yu, H.S., Li, W.C., Ko, Y.C., Chen, G.S., Wu, C.S., Lu, Y.W., Yang, Y.H. and Lan, C.C. (2013) Arthritis as an Important Determinant for Psoriatic Patients to Develop Severe Vascular Events in Taiwan: A Nation-Wide Study. Journal of the European Academy of Dermatology and Venereology, 27, 1262-1268.
|
[78]
|
Prodanovich, S., Ma, F., Taylor, J.R., Pezon, C., Fasihi, T. and Kirsner, R.S. (2005) Methotrexate Reduces Incidence of Vascular Diseases in Veterans with Psoriasis or Rheumatoid Arthritis. Journal of the American Academy of Dermatology, 52, 262-267. https://doi.org/10.1016/j.jaad.2004.06.017
|
[79]
|
Wu, J.J., Poon, K.Y., Channual, J.C. and Shen, A.Y. (2012) Association between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients with Psoriasis. Archives of Dermatology, 148, 1244-1250.
https://doi.org/10.1001/archdermatol.2012.2502
|
[80]
|
Wu, J.J. and Poon, K.Y. (2013) Association of Ethnicity, Tumor Necrosis Factor Inhibitor Therapy, and Myocardial Infarction Risk in Patients with Psoriasis. Journal of the American Academy of Dermatology, 69, 167-168.
https://doi.org/10.1016/j.jaad.2013.02.019
|
[81]
|
Wu, J.J., Poon, K.Y. and Bebchuk, J.D. (2013) Association between the Type and Length of Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients with Psoriasis. Journal of Drugs in Dermatology, 12, 899-903.
|
[82]
|
Wu, J.J., Poon, K.Y. and Bebchuk, J.D. (2014) Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients with Psoriasis, Psoriatic Arthritis, or Both. Journal of Drugs in Dermatology, 13, 932-934.
|
[83]
|
Wu, J.J., Guerin, A., Sundaram, M., Dea, K., Cloutier, M. and Mulani, P. (2017) Cardiovascular Event Risk Assessment in Psoriasis Patients Treated with Tumor Necrosis Factor-Alpha Inhibitors versus Methotrexate. Journal of the American Academy of Dermatology, 76, 81-90. https://doi.org/10.1016/j.jaad.2016.07.042
|
[84]
|
Tabas, I., Williams, K.J. and Borén, J. (2007) Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications. Circulation, 116, 1832-1844.
https://doi.org/10.1161/CIRCULATIONAHA.106.676890
|
[85]
|
Alexander, M.R., et al. (2012) Genetic Inactivation of IL-1 Signaling Enhances Atherosclerotic Plaque Instability and Reduces Outward Vessel Remodeling in Advanced Atherosclerosis in Mice. Journal of Clinical Investigation, 122, 70.
https://doi.org/10.1172/JCI43713
|
[86]
|
Tabas, I. and Glass, C.K. (2013) Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities. Science, 339, 166-172.
https://doi.org/10.1126/science.1230720
|
[87]
|
Moreira-Navarrete,V., et al. (2013) Effectiveness of Canakinumab In a Cryopyrin-Associated Periodic Syndrome Cohort. 2013 ACR/ARHP Annual Meeting, A Single Center Experience, Abstract Number: 1205, 25-30 October 2013, San Diego, CA.
|
[88]
|
Stamp, L., et al. (2006) The Use of Low Dose Methotrexate in Rheumatoid Arthritis—Are We Entering a New Era of Therapeutic Drug Monitoring and Pharmacogenomics? Biomedicine and Pharmacotherapy, 60, 678-687.
https://doi.org/10.1016/j.biopha.2006.09.007
|
[89]
|
Pater, C. and Severin T. (2013) Management of Acute Heart Failure. Is There a Paradigm Shift around the Corner? World Journal of Cardiovascular Diseases, 3, 1-7.
|
[90]
|
Tahara, N., Kai, H., Ishibashi, M., Nakaura, H., Kaida, H., Baba, K., Hayabuchi, N. and Imaizumi, T. (2006) Simvastatin Attenuates Plaque Inflammation: Evaluation by Fluorodeoxyglucose Positron Emission Tomography. Journal of the American College of Cardiology, 48, 1825-1831. https://doi.org/10.1016/j.jacc.2006.03.069
|
[91]
|
Joshi, A.A., Lerman, J.B., Aberra, T.M., Afshar, M., Teague, H.L., Rodante, J.A., Krishnamoorthy, P., Ng, Q., Aridi, T.Z., Salahuddin, T., et al. (2016) GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. Circulation Research, 119, 1242-1253.
https://doi.org/10.1161/CIRCRESAHA.116.309637
|
[92]
|
Liao, Y., Jiang, H. and Hu, X. (2016) Increased Serum IL-17A Is Associated with HMGB1 in Coronary Artery Disease. International Journal of Clinical and Experimental Medicine, 9, 11772-11779.
|
[93]
|
Harrington, L.E., Hatton, R.D., Mangan, P.R., et al. (2005) Interleukin 17-Producing CD4+ Effector T Cells Develop via a Lineage Distinct from the T Helper Type 1 and 2 Lineages. Nature Immunology, 6, 1123-1132.
https://doi.org/10.1038/ni1254
|
[94]
|
Bettelli, E., Korn, T. and Kuchroo, V.K. (2007) Th17: The Third Member of the Effector T Cell Trilogy. Current Opinion in Immunology, 19, 652-657.
https://doi.org/10.1016/j.coi.2007.07.020
|
[95]
|
Kim, T.G., Kim, S. and Lee, M.G. (2017) The Origin of Skin Dendritic Cell Network and Its Role in Psoriasis. International Journal of Molecular Sciences, 19, 42.
https://doi.org/10.3390/ijms19010042
|
[96]
|
Piskin, G., Sylva-Steenland, R.M.R., Bos, J.D. and Teunissen, M.B.M. (2006) In Vitro and in Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin. The Journal of Immunology, 176, 1908-1915. https://doi.org/10.4049/jimmunol.176.3.1908
|
[97]
|
McKenzie, B.S., Kastelein, R.A. and Cua, D.J. (2006) Understanding the IL-23-IL-17 Immune Pathway. Trends in Immunology, 27, 17-23.
https://doi.org/10.1016/j.it.2005.10.003
|
[98]
|
Veldhoen, M. (2014) Interleukin 17 Is a Chief Orchestrator of Immunity. Nature Immunology, 18, 612-621. https://doi.org/10.1038/ni.3742
|
[99]
|
Gaffen, S.L., Jain, R., Garg, A.V. and Cua, D.J. (2014) The IL-23-IL-17 Immune Axis: From Mechanisms to Therapeutic Testing. Nature Reviews Immunology, 14, 585-600.
https://doi.org/10.1038/nri3707
|
[100]
|
Taleb, S., Tedgui, A. and Mallat, Z. (2015) IL-17 and Th17 Cells in Atherosclerosis: Subtle and Contextual Roles. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 258-264. https://doi.org/10.1161/ATVBAHA.114.303567
|
[101]
|
McInnes, I.B. and Schett, G. (2007) Cytokines in the Pathogenesis of Rheumatoid Arthritis. Nature Reviews Immunology, 7, 429-442. https://doi.org/10.1038/nri2094
|
[102]
|
Armstrong, A.W., Harskamp, C.T., Ledo, L., et al. (2012) Coronary Artery Disease in Patients with Psoriasis Referred for Coronary Angiography. American Journal of Cardiology, 109, 976-980. https://doi.org/10.1016/j.amjcard.2011.11.025
|
[103]
|
Armstrong, A.W., Harskamp, C.T. and Armstrong, E.J. (2013) Psoriasis and the Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. JAMA Dermatology, 149, 84-91. https://doi.org/10.1001/2013.jamadermatol.406
|
[104]
|
Armstrong, A.W., Harskamp, C.T. and Armstrong, E.J. (2013) Psoriasis and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Observational Studies. Journal of the American Academy of Dermatology, 68, 654-662.
https://doi.org/10.1016/j.jaad.2012.08.015
|
[105]
|
Armstrong, A.W., Harskamp, C.T. and Armstrong, E.J. (2013) The Association between Psoriasis and Hypertension: A Systematic Review and Meta-Analysis of Observational Studies. Journal of Hypertension, 31, 433-443.
https://doi.org/10.1097/HJH.0b013e32835bcce1
|
[106]
|
Cosmi, L., Maggi, L., Santarlasci, V., Liotta, F. and Annunziato, F. (2014) T Helper Cells Plasticity in Inflammation. Cytometry Part A, 85, 36-42.
https://doi.org/10.1002/cyto.a.22348
|
[107]
|
Maradit-Kremers, H., Icen, M., Ernste, F.C., Dierkhising, R.A. and McEvoy, M.T. (2012) Disease Severity and Therapy as Predictors of Cardiovascular Risk in Psoriasis: A Population-Based Cohort Study. Journal of the European Academy of Dermatology and Venereology, 26, 336-343.
https://doi.org/10.1111/j.1468-3083.2011.04071.x
|
[108]
|
Langan, S.M., Seminara, N.M., Shin, D.B., et al. (2012) Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. Journal of Investigative Dermatology, 132, 556-562.
https://doi.org/10.1038/jid.2011.365
|
[109]
|
Naik, H.B., Natarajan, B., Stansky, E., et al. (2015) Severity of Psoriasis Associates with Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 2667-2676. https://doi.org/10.1161/ATVBAHA.115.306460
|
[110]
|
Ahlehoff, O., Gislason, G.H., Lindhardsen, J., et al. (2011) Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study. PLoS ONE, 6, e18125. https://doi.org/10.1371/journal.pone.0018125
|
[111]
|
Golden, J.B., McCormick, T.S. and Ward, N.L. (2013) IL-17 in Psoriasis: Implications for Therapy and Cardiovascular Co-Morbidities. Cytokine, 62, 195-201.
https://doi.org/10.1016/j.cyto.2013.03.013
|
[112]
|
Speah, F. (2008) Inflammation in Atherosclerosis and Psoriasis: Common Pathogenic Mechanisms and the Potential for an Integrated Treatment Approach. British Journal of Dermatology, 159, 10-17.
https://doi.org/10.1111/j.1365-2133.2008.08780.x
|
[113]
|
Armstrong, A.W., Voyles, S.V., Armstrong, E.J., et al. (2011) A Tale of Two Plaques: Convergent Mechanisms of T-Cell-Mediated Inflammation in Psoriasis and Atherosclerosis. Experimental Dermatology, 20, 544-549.
https://doi.org/10.1111/j.1600-0625.2011.01308.x
|
[114]
|
Schüler, S., Brand, A., Klebow, S., Johannes, Wild, J., ProtásioVeras, F., Ullmann, E., Roohani, S., Kolbinger, F., Kossmann, S., Wohn, C., Daiber, A., Münzel, T., Wenzel, P., Waisman, A., Clausen, B.E. and Karbach, S. (2018) Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis. Journal of Investigative Dermatology, 139, 638-647.
|
[115]
|
Wohn, C., Brand, A., Van Ettinger, K., Brouwers-Haspels, I., Waisman, A., Laman, J.D., et al. (2016) Gradual Development of Psoriatic Skin Lesions by Constitutive Low-Level Expression of IL-17A. Cellular Immunology, 308, 57-65.
https://doi.org/10.1016/j.cellimm.2015.11.006
|
[116]
|
Madhur, M.S., Lob, H.E., McCann, L.A., Iwakura, Y., Blinder, Y., Guzik, T.J., et al. (2010) Interleukin 17 Promotes Angiotensin II-Induced Hypertension and Vascular Dysfunction. Hypertension, 55, 500-507.
https://doi.org/10.1161/HYPERTENSIONAHA.109.145094
|
[117]
|
Saleh, M.A., Norlander, A.E. and Madhur, M.S. (2016) Inhibition of Interleukin 17-A but Not Interleukin-17F Signaling Lowers Blood Pressure and Reduces End-Organ Inflammation in Angiotensin II-Induced Hypertension. JACC: Basic to Translational Science, 1, 606-616. https://doi.org/10.1016/j.jacbts.2016.07.009
|
[118]
|
Huang, L.H., et al. (2018) Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis. Cell Metabolism, 29, 475-487.
|
[119]
|
Zhang, S., Yuan, J., Yu, M., Fan, H., Guo, Z.Q., Yang, R., Guo, H.P., Liao, Y.H. and Wang, M. (2012) IL-17A Facilitates Platelet Function through the ERK2 Signaling Pathway in Patients with Acute Coronary Syndrome. PLoS ONE, 7, e40641.
https://doi.org/10.1371/journal.pone.0040641
|
[120]
|
Hashmi, S. and Zeng, Q.T. (2006) Role of Interleukin-17 and Interleukin-17-Induced Cytokines Interleukin-6 and Interleukin-8 in Unstable Coronary Artery Disease. Coronary Artery Disease, 17, 699-706.
https://doi.org/10.1097/01.mca.0000236288.94553.b4
|
[121]
|
Jafarzadeh, A., Esmaeeli-Nadimi, A., Noughts, H., Nematoid, M. and Rezayati, M.T. (2009) Serum Levels of Interleukin (IL)-13, IL-17 and IL-18 in Patients with Ischemic Heart Disease. Anadolu Kardiyoloji Dergisi, 9, 75-83.
|
[122]
|
Kalinina, N., Agrotis, A., Antropova, Y., DiVitto, G., Kanellakis, P., Kostolias, G., Ilyinskaya, O., Tararak, E. and Bobik, A. (2004) Increased Expression of the DNA-Binding Cytokine HMGB1 in Human Atherosclerotic Lesions: Role of Activated Macrophages and Cytokines. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 2320-2325. https://doi.org/10.1161/01.ATV.0000145573.36113.8a
|
[123]
|
De Boer, O.J., Li, X., Teeling, P., Mackaay, C., Ploegmakers, H.J., Van Der Loos, C.M., Daemen, M.J., De Winter, R.J. and Van Der Wal, A.C. (2013) Neutrophils, Neutrophil Extracellular Traps and Interleukin-17 Associate with the Organisation of Thrombi in Acute Myocardial Infarction. Thrombosis and Haemostasis, 109, 290-297.
https://doi.org/10.1160/TH12-06-0425
|
[124]
|
Elnabawi, Y.A., Dey, A.K., Goyal, A. and Groenendyk, J.W., et al. (2019) Coronary Artery Plaque Characteristics and Treatment with Biologic Therapy in Severe Psoriasis: Results from a Prospective Observational Study. Cardiovascular Research, 115, 721-728.
|
[125]
|
Zhang, L., Zhang, J., Su, S. and Luo, S. (2019) Changes in Interleukin-27 Levels in Patients with Acute Coronary Syndrome and Their Clinical Significance. PeerJ, 7, e5652. https://doi.org/10.7717/peerj.5652
|
[126]
|
Rominger, A., Saam, T., Wolpers, S., Cyran, C.C., Schmidt, M., Foerster, S., Nikolaou, K., Reiser, M.F., Bartenstein, P. and Hacker, M. (2009) 18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease. Journal of Nuclear Medicine, 50, 1611-1620.
https://doi.org/10.2967/jnumed.109.065151
|
[127]
|
Mehta, N.N., Yu, Y., Saboury, B., Foroughi, N., Krishnamoorthy, P., Raper, A., Baer, A., Antigua, J., Van Voorhees, A.S., Torigian, D.A., et al. (2011) Systemic and Vascular Inflammation in Patients with Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG-PET/CT): A Pilot Study. Archives of Dermatology, 147, 1031-1039.
https://doi.org/10.1001/archdermatol.2011.119
|
[128]
|
Voros, S., Rinehart, S., Qian, Z., Joshi, P., Vazquez, G., Fischer, C., Belur, P., Hulten, E.; Villines, T.C. (2011) Coronary Atherosclerosis Imaging by Coronary CT Angiography: Current Status, Correlation with Intravascular Interrogation and Meta-Analysis. JACC: Cardiovascular Imaging, 4, 537-548.
https://doi.org/10.1016/j.jcmg.2011.03.006
|
[129]
|
Ludwig, R.J., Herzog, C., Rostock, A., Ochsendorf, F.R., Zollner, T.M., Thaci, D., Kaufmann, R., Vogl, T.J. and Boehncke, WH. (2007) Psoriasis: A Possible Risk Factor for Development of Coronary Artery Calcification. British Journal of Dermatology, 156, 271-276. https://doi.org/10.1111/j.1365-2133.2006.07562.x
|
[130]
|
Yiu, K.H., Yeung, C.K., Zhao, C.T., Chan, J.C., Siu, C.W., Tam, S., Wong, C.S., Yan, G.H., Yue,W.S., Khong, P.L., et al. (2013) Prevalence and Extent of Subclinical Atherosclerosis in Patients with Psoriasis. Journal of Internal Medicine, 273, 273-282. https://doi.org/10.1111/joim.12002
|
[131]
|
Torres, T., Bettencourt, N., Mendonca, D., Vasconcelos, C., Gama, V., Silva, B.M. and Selores, M. (2015) Epicardial Adipose Tissue and Coronary Artery Calcification in Psoriasis Patients. Journal of the European Academy of Dermatology and Venereology, 29, 270-277. https://doi.org/10.1111/jdv.12516
|
[132]
|
Honma, M., Shibuya, T., Iwasaki, T., Iinuma, S., Takahashi, N., Kishibe, M., Minami-Hori, M. and Ishida-Yamamoto, A. ((2017) Prevalence of Coronary Artery Calcification in Japanese Patients with Psoriasis: A Close Correlation with Bilateral Diagonal Earlobe Creases. The Journal of Dermatology, 44, 1122-1128.
https://doi.org/10.1111/1346-8138.13895
|
[133]
|
Balci, A., Celik, M., Balci, D.D., Karazincir, S., Yonden, Z., Korkmaz, I., Celik, E. and Egilmez, E. (2014) Patients with Psoriasis Have an Increased Amount of Epicardial Fat Tissue. Clinical and Experimental Dermatology, 39, 123-128.
https://doi.org/10.1111/ced.12216
|
[134]
|
Turner, J.E., Paust, H.J., Steinmetz, O.M. and Panzer, U. (2010) The Th17 Immune Response in Renal Inflammation. Kidney International, 77, 1070-1075.
https://doi.org/10.1038/ki.2010.102
|
[135]
|
Hammerich, L., Heymann, F. and Tacke, F. (2011) Role of IL-17 and Th17 Cells in Liver Diseases. Clinical and Developmental Immunology, 2011, Article ID: 345803.
|
[136]
|
Zhang, S., Huang, D., Weng, J., Huang, Y., Liu, S., Zhang, Q., et al. (2016) Neutralization of Interleukin-17 Attenuates Cholestatic Liver Fibrosis in Mice. Scandinavian Journal of Immunology, 83, 102. https://doi.org/10.1111/sji.12395
|
[137]
|
Wang, Z., Shi, W., Liang, X., Wang, W. and Liang, J. (2016) Association of Interleukin 17/Angiotensin II with refractory Hypertension Risk in Hemodialysis Patients. African Health Sciences, 16, 766-771.
|
[138]
|
McMaster, W.G., Kirabo, A., Madhur, M.S. and Harrison, D.G. (2015) Inflammation, Immunity, and Hypertensive End-Organ Damage. Circulation Research, 116, 1022. https://doi.org/10.1161/CIRCRESAHA.116.303697
|
[139]
|
Elain, G., Jeanneau, K., Rutkowska, A., Mir, A.K. and Dev, K.K. (2014) The Selective Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) Attenuates IL17A-Induced Levels of IL6 in Human Astrocytes. Glia, 62, 725-735.
https://doi.org/10.1002/glia.22637
|
[140]
|
https://acrabstracts.org/abstract/bms-986195-is-a-highly-selective-and-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-with-robust-efficacy-at-low-doses-in-preclinical-models-of-ra-and-lupus-nephritis/
|
[141]
|
https://www.globalbankingandfinance.com/can-fite-biopharma-ceo-letter-to-shareholders/
|
[142]
|
https://www.affibody.se/affibody-announces-initial-results-from-a-phase-i-study-of-aby-035/
|
[143]
|
Huh, J.R. and Littman, D.R. (2012). Small Molecule Inhibitors of RORγt: Targeting Th17 Cells and Other Applications. European Journal of Immunology, 42, 2232-2237. https://doi.org/10.1002/eji.201242740
|
[144]
|
https://nuevolution.com/wp-content/uploads/2019/03/2-Page-Flyer-Nuevolution_February_2019.pdf
|
[145]
|
Von Stebut, E., et al. (2019) Impact of Secukinumab on Endothelial Dysfunction and Cardiovascular Disease Parameters in Psoriasis Patients over 52 weeks. Journal of Investigative Dermatology, in press.
|
[146]
|
ClinicalTrials.gov. Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S).
https://clinicaltrials.gov/ct2/show/NCT03055494
|
[147]
|
https://www.corrona.org/
|